News (English) - World Health Organization
Corporate news releases, statements, and notes for media issued by the World Health Organization.

Improving understanding of and response to infodemics during public health emergencies

Following the first global infodemiology conference held in July 2020, WHO and partners coordinated a joint call for papers  with 5 academic journals representing different scientific fields, all related to components of the science behind managing infodemics. This week the first of these academic journals published its special infodemic feature. The research findings contribute to filling the knowledge gap identified through the WHO public health research agenda for managing infodemics released earlier this month.

In the issue published by Health Security, you’ll find original peer-reviewed articles that address practice- and research-based analysis of misinformation during epidemics, characteristics of successful online messaging, disinformation and epidemics in the context of biowarfare, understanding the impact of different news sources on risk perception, and use of community listening and feedback to respond to false information. The commentaries focus on the COVID-19 pandemic in the context of crisis and emergency risk communication, scientific situational awareness, and approaches to social media messaging.

Through research being published, the science of infodemic management will be built on solid and scientifically tested methods and analytics, all of which can contribute to the design of policies and interventions that will help health authorities monitor, evaluate and respond to the current and future infodemics. 

No-fault compensation programme for COVID-19 vaccines is a world first

  • New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts
  • This is the first and only global vaccine injury compensation mechanism
  • The programme is funded by a small levy on each dose supported by the Gavi COVAX AMC  

 

The World Health Organization (WHO) and Chubb Limited (NYSE: CB), through ESIS Inc., a Chubb company, signed an agreement on behalf of the COVAX Facility on 17 February 2021 for the administration of a no-fault compensation programme for the 92 low- and middle-income countries and economies eligible for support via the Gavi COVAX Advance Market Commitment (AMC) of the COVAX Facility.

As the first and only vaccine injury compensation mechanism operating on an international scale, the programme will offer eligible individuals in AMC-eligible countries and economies a fast, fair, robust and transparent process to receive compensation for rare but serious adverse events associated with COVAX-distributed vaccines until 30 June 2022.

By providing a no-fault lump-sum compensation in full and final settlement of any claims, the COVAX programme aims to significantly reduce the need for recourse to the law courts, a potentially lengthy and costly process.

ESIS, as the independent administrator of the programme, was selected in accordance with WHO’s procurement rules and procedures, and charges no fees to applicants.

All vaccines procured or distributed through the COVAX Facility receive regulatory approval or an emergency use authorization to confirm their safety and efficacy.

But, as with all medicines, even vaccines that are approved for general use may, in rare cases, cause serious adverse reactions.

 “The unprecedented nature of the COVID-19 pandemic has been matched by the largest ever rollout of new vaccines under the ACT-Accelerator and its vaccines pillar, COVAX. This no-fault compensation mechanism helps to ensure that people in AMC-eligible countries and economies can benefit from the cutting-edge science that has delivered COVID-19 vaccines in record time,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “We are pleased to be collaborating with Chubb, which has the capabilities to support the COVAX facility through its global network and claims handling ability. WHO’s agreement with Chubb offers further protection and confidence in the life-saving power of vaccines.”

“The No-Fault Compensation fund is a massive boost for COVAX’s goal of equitable global access to vaccines: by providing a robust, transparent and independent mechanism to settle serious adverse events it helps those in countries who might have such effects, manufacturers to roll out vaccines to countries faster, and is a key benefit for lower-income governments procuring vaccines through the Gavi COVAX AMC,” said Dr Seth Berkley, CEO of Gavi.

The COVAX no-fault compensation programme will be operationalized through its web portal (www.covaxclaims.com) by 31 March 2021, which will include resources such as the programme’s protocol, Frequently Asked Questions (FAQs) and information on how to submit an application.

Eligible individuals may apply for compensation under the programme once the portal becomes operational, even if a COVAX-distributed vaccine is administered to them before 31 March 2021.

The programme is financed initially through Gavi COVAX AMC donor funding, calculated as a levy charged on all doses of COVID-19 vaccines distributed through the COVAX Facility to the AMC eligible economies until 30 June 2022.

WHO is working with Chubb to secure insurance coverage for the programme with Chubb as lead insurer.

Chubb is proud and honoured to work with the World Health Organization and its partners on the critically important COVAX programme,” said Evan G. Greenberg, Chairman and Chief Executive Officer of Chubb. “The COVID-19 pandemic has had a devastating effect on people and economies around the globe, and the development and deployment of efficacious vaccines is a crucial step toward ending this crisis. However, a vaccination strategy is only as effective as the number of people it reaches, which is why the COVAX facility is so critical. Access to the protection offered by a vaccine should not be limited or restricted. All countries, regardless of income levels, should have equal access to these life-saving vaccines.”

The delivery of COVID-19 vaccines during 2021 will be the fastest and largest global deployment of novel vaccines in history. The COVAX Facility aims, by the end of 2021, to deliver at least 2 billion doses of safe, effective and quality-assured vaccines to all participating countries, including at least 1.3 billion doses to the 92 AMC-eligible countries and economies, at the same time as wealthier nations.

***

ABOUT the COVAX Facility

The Gavi-administered COVAX Facility forms a key part of the COVAX pillar (COVAX) of the Access to COVID-19 Tools (ACT) Accelerator, a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, working in partnership with developed and developing country vaccine manufacturers. 
 

ABOUT WHO

The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from 149 offices, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing. 

For updates on COVID-19 and public health advice, visit www.who.int and follow WHO on TwitterFacebookInstagramLinkedInTikTokPinterestSnapchatYouTubeTwitch 


 ABOUT Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 822 million children – and prevented more than 14 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org and connect with us on Facebook and Twitter.

The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi’s work here.

 

ABOUT CHUBB

Chubb is the world's largest publicly traded property and casualty insurance company. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. As an underwriting company, we assess, assume and manage risk with insight and discipline. We service and pay our claims fairly and promptly. The company is also defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb maintains executive offices in Zurich, New York, London, Paris and other locations, and employs approximately 31,000 people worldwide. Additional information can be found at: www.chubb.com .


 ABOUT ESIS, A CHUBB COMPANY

ESIS, Inc. provides claim and risk management services to a wide variety of commercial clients. Our innovative best-in-class approach to program design, integration, and achievement of results aligns with the needs and expectations of our clients' unique risk management needs. With more than 66 years of experience and offerings in both the U.S. and globally, ESIS provides one of the industry's broadest selections of risk management solutions covering both pre- and post-loss services.

 

 

WHO Director-General's statement on Tanzania and COVID-19

We extend our condolences to our Tanzanian sisters and brothers on the recent passing of a senior Tanzanian leader as well as the government’s Chief Secretary.

In late January, I joined Dr Matshidiso Moeti, the WHO Director for the African Region, in urging Tanzania to scale public health measures against COVID-19 and to prepare for vaccination. I also encouraged the sharing of data in light of reports of COVID-19 cases among travellers.

Since then I have spoken with several authorities in Tanzania but WHO is yet to receive any information regarding what measures Tanzania is taking to respond to the pandemic.

This situation remains very concerning. I renew my call for Tanzania to start reporting COVID-19 cases and share data. I also call on Tanzania to implement the public health measures that we know work in breaking the chains of transmission, and to prepare for vaccination.

A number of Tanzanians travelling to neighbouring countries and beyond have tested positive for COVID-19. This underscores the need for Tanzania to take robust action both to safeguard their own people and protect populations in these countries and beyond.

COVID-19 is a serious disease that can cause severe illness and even death. National authorities everywhere must do all they can to protect people and save lives and WHO stands ready to support them in the response against this deadly virus.

 

 




ደረጃ 3 ክትባት ዕጩዎች

BNT162mRNA-1273Ad5-nCoVAZD1222CoronaVacCovaxinJNJ-78436735 (formerly Ad26.COV2.S)No name announcedNVX-CoV2373Sputnik V
አሁኑ ጊዜ በኢትዮጵያ የኮሮና ወረርሺኝ

Put your cursor or your finger on the chart and rotate. Tap on the color indicators
በሽታ COVID-19
Virus strain SARS-CoV-2
ቦታ  Ethiopia
የመጀመሪያ ሪፖርት አዲስ አበባ
ቀን አርብ፣13 መጋቢት 2020
የተገኘበት ሰው ጃፓናዊ
አጠቃላይ ኬዝ 243,631
ያገገሙ 180,645
የሞቱ
3,392
አገራቸው የተመለሱ
2
አሁን ያሉ ኬዞች
59,594
የተመረመሩ
2,507,403
አጠቃላይ ኬዞች በሚሊዮን
2,078(0.20%)
ያገገሙ በሚሊዮን
1,541(0.15%)
ሞት በሚሊዮን
29(0.00%)
ጽኑ ህክምና በሚሊዮን
8(0.00%)
አሁን ላይ ያሉ ኬዞች በሚሊዮን
508(0.05%)
የተመረመሩ በሚሊዮን
21,390 (2.13%)
ህዝብ ቁጥር
117,221,556
Loading

ወቅታዊ መረጃ


አጠቃላይ Case
143,193,032
ያገገሙ
121,795,839
የሞቱ
3,049,591
አሁን ላይ የተያዙ
18,347,602